Table 1.
Baseline characteristics of patients administered tenofovir (TDF) or entecavir (ETV).
| ETV (n = 66) | TDF (n = 30) | p | |
|---|---|---|---|
| Age, years | 35.1 ± 4.5 | 33.7 ± 4.6 | 0.28 |
| Gender, male | 74.2% (49/66) | 76.7% (23/30) | 1.00 |
| Height (cm) | 167.09 ± 7.22 | 164.93 ± 7.45 | 0.19 |
| Weight (kg) | 62.58 ± 10.43 | 58.37 ± 7.98 | 0.05 |
| History of alcohol use | 21.2% (14/66) | 26.7% (8/30) | 0.61 |
| History of smoking | 19.7% (13/66) | 26.7% (8/30) | 0.44 |
| Family history of Hepatitis B | 71.2% (47/66) | 70.0% (21/30) | 1.00 |
| Pretreatment HBV-DNA, log10 IU/mL | 7.33 ± 0.79 | 7.25 ± 0.83 | 0.62 |
| Pretreatment serum ALT, U/L | 154.59 ± 122.05 | 168.53 ± 112.39 | 0.60 |
| Elevated serum ALT before therapy | 93.9% (62/66) | 96.7% (29/30) | 0.58 |
IU/mL, international unit per milliliter; U/L, unit per liter; ALT, alanine aminotransferase.